JP2022534966A5 - - Google Patents
Info
- Publication number
- JP2022534966A5 JP2022534966A5 JP2021570756A JP2021570756A JP2022534966A5 JP 2022534966 A5 JP2022534966 A5 JP 2022534966A5 JP 2021570756 A JP2021570756 A JP 2021570756A JP 2021570756 A JP2021570756 A JP 2021570756A JP 2022534966 A5 JP2022534966 A5 JP 2022534966A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- actrii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025067310A JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854625P | 2019-05-30 | 2019-05-30 | |
| US62/854,625 | 2019-05-30 | ||
| PCT/US2020/035148 WO2020243448A1 (en) | 2019-05-30 | 2020-05-29 | Actrii-binding proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067310A Division JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534966A JP2022534966A (ja) | 2022-08-04 |
| JP2022534966A5 true JP2022534966A5 (https=) | 2023-06-06 |
| JP7669291B2 JP7669291B2 (ja) | 2025-04-28 |
Family
ID=73553540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570756A Active JP7669291B2 (ja) | 2019-05-30 | 2020-05-29 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| JP2025067310A Pending JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067310A Pending JP2025118664A (ja) | 2019-05-30 | 2025-04-16 | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12545736B2 (https=) |
| EP (1) | EP3976630A4 (https=) |
| JP (2) | JP7669291B2 (https=) |
| KR (1) | KR20220029563A (https=) |
| CN (1) | CN114127087A (https=) |
| AU (1) | AU2020284038A1 (https=) |
| CA (1) | CA3142149A1 (https=) |
| WO (1) | WO2020243448A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7669291B2 (ja) | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| WO2022192411A1 (en) * | 2021-03-10 | 2022-09-15 | Acceleron Pharma Inc. | Actrii-alk4 antagonists and methods of treating heart failure |
| JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
| TW202328190A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商來凱醫藥科技（上海）有限公司 | 抗acvr2a抗體及其用途 |
| WO2025027052A1 (en) | 2023-07-31 | 2025-02-06 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025026353A1 (en) * | 2023-08-01 | 2025-02-06 | Laekna Therapeutics Shanghai Co., Ltd. | Anti-acvr2b antibodies and uses thereof |
| TW202521582A (zh) * | 2023-09-28 | 2025-06-01 | 瑞士商六峰生物股份有限公司 | 靶向ActRIIA及ActRIIB之抗體 |
| CN121344183B (zh) * | 2025-12-18 | 2026-03-27 | 成都医学院 | 检测ACVR2b的试剂在制备慢性肾脏病血管钙化诊断试剂盒中的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| PE20120532A1 (es) | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| NZ703724A (en) | 2012-06-11 | 2017-06-30 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| WO2014172448A2 (en) | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| US20170240639A1 (en) * | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
| CN116284392A (zh) * | 2016-03-10 | 2023-06-23 | 艾科赛扬制药股份有限公司 | 活化素2型受体结合蛋白及其用途 |
| LT3600415T (lt) | 2017-03-24 | 2025-12-29 | Novartis Ag | Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui |
| JP7669291B2 (ja) | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
-
2020
- 2020-05-29 JP JP2021570756A patent/JP7669291B2/ja active Active
- 2020-05-29 CN CN202080051148.1A patent/CN114127087A/zh active Pending
- 2020-05-29 US US17/615,474 patent/US12545736B2/en active Active
- 2020-05-29 CA CA3142149A patent/CA3142149A1/en active Pending
- 2020-05-29 EP EP20814343.8A patent/EP3976630A4/en active Pending
- 2020-05-29 WO PCT/US2020/035148 patent/WO2020243448A1/en not_active Ceased
- 2020-05-29 AU AU2020284038A patent/AU2020284038A1/en active Pending
- 2020-05-29 KR KR1020217040678A patent/KR20220029563A/ko active Pending
-
2025
- 2025-04-16 JP JP2025067310A patent/JP2025118664A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534966A5 (https=) | ||
| JP2024026159A5 (https=) | ||
| TWI803876B (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 | |
| TWI631136B (zh) | 單特異性及雙特異性抗ｉｇｆ－１ｒ及抗ｅｒｂｂ３抗體 | |
| JP2019513015A5 (https=) | ||
| EP2259795B1 (en) | Anti-vegf antibody | |
| EP3041862B1 (en) | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies | |
| JP5738294B2 (ja) | 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物 | |
| KR101852915B1 (ko) | 과립구-대식세포 콜로니 자극 인자에 대한 항체 | |
| CA2680085C (en) | Hutnfr1 selective antagonists | |
| TWI815305B (zh) | Pd-1/vegf四價雙特異性抗體、其製備方法和用途 | |
| CN106632674A (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
| EP4303231A1 (en) | Bispecific antibody | |
| JP2019515676A5 (https=) | ||
| WO2010019656A9 (en) | Humanized anti-rage antibody | |
| US20230391869A1 (en) | Inhibition of platelet aggregation using anti-human gpvi antibodies | |
| IL301473A (en) | EGFR binding complex and how it is created and used | |
| JP2022534514A5 (https=) | ||
| JP2021500895A5 (https=) | ||
| EP4155322A1 (en) | Anti-trka antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof | |
| TWI918721B (zh) | Egfr結合複合物及其製備和使用方法 | |
| US20260109769A1 (en) | Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use | |
| TW202409093A (zh) | 融合蛋白 | |
| CN107840886A (zh) | Gm‑csf抗体及其用途 | |
| WO2026080752A2 (en) | De novo antibodies to activin a receptor like type 1 (alk1) |